Neuraxis, INC (NRXS) Form 10-Q — Aug 11, 2026
NeurAxis more than doubled second-quarter revenue to $1.93 million, up 115.7% year over year, driven by the IB-Stim Category I CPT code effective January 1, 2026 and broader commercial insurance coverage. Gross margin improved to 85.9% as more units sold with full reimbursement rather than through the discounted financial assistance program. Despite the growth, the quarterly net loss widened 23.4% to $2.09 million, and the company disclosed that substantial doubt exists about its ability to continue as a going concern.
Key figures
- Revenue
- 1928695
- Total Debt
- 42726
- Revenue Yoy
- 115.7% Q2 YoY; 97.6% six-month YoY
- Total Assets
- 9996160
- Cash Position
- 8322258
- Shares Outstanding
- 12557765
- Q2 gross margin
- 85.9%
- Q2 2025 net sales
- 894086
- Q2 2026 net sales
- 1928695
- Stockholders equity
- 6735053
- Working capital surplus
- 6317762
- Six month 2025 net sales
- 1789741
- Six month 2026 net sales
- 3536578
- Atm gross proceeds six months
- 5061018
- Upcoming incremental stock comp
- 3400000
- Series b dividends paid in stock
- 1215264
- Upcoming cash taxes rsu exchange
- 3000000
- Warrant exercise proceeds six months
- 943970
Price after filing
Close on the filing date to close N calendar days later (from $7.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.